Key Insights• The France biosurgery market represents one of the largest and most sophisticated national markets for surgical biomaterials in Europe. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The France biosurgery market is distinguished by its universal healthcare system (Assurance Maladie), advanced clinical infrastructure, and significant surgical volumes. According to available data, France recorded more than 9 million surgical interventions in 2024, a figure that has tripled over 45 years. Cataract surgeries lead with 1.1 million procedures, followed by hip and knee prostheses. Healthcare expenditure in France represented approximately 11.28% to 11.5% of GDP in 2025 among the highest in the OECD with total health spending reaching approximately €333 billion (11.4% of GDP). The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models.• France is the second-largest medical device market in Europe (behind Germany) and one of the top five globally.

The country is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both public hospitals and private clinics.• France recorded more than 9 million surgical interventions in 2024, a figure that has tripled in 45 years. Cataract surgeries lead with 1.1 million procedures, followed by hip and knee prostheses. Bone-Graft Substitutes represent the largest product category within the French biosurgery market, driven by the high volume of orthopedic procedures. Hip and knee prostheses are among the most frequently performed surgeries in France.• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques across French hospitals and clinics. France's aging population represents a significant long-term demand driver. As of January 1, 2025, 14.9 million people (22% of the population) residing in France were aged 65 years or older.

This proportion has increased by 5 percentage points in 20 years.Market Outlook• According to the research report, "France Biosurgery Market Overview, 2031," published by Actual Market Research, the France Biosurgery Market is anticipated to grow at more than 5.62% CAGR from 2026 to 2031.The French biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both public hospitals and private clinics. The market's growth trajectory is intrinsically linked to the broader French healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.• France's healthcare expenditure continues to rise, representing approximately 11.28% to 11.5% of GDP in 2025 among the highest in the OECD. Total health spending reached approximately €333 billion (11.4% of GDP) in 2025. Healthcare spending as a share of GDP in France is the highest proportion in the EU.The aging French population represents the most significant long-term demand driver. As of January 1, 2025, 14.9 million people (22% of the population) residing in France were aged 65 years or older. Life expectancy reached record highs of 85.9 years for women and 80.3 years for men.

As this demographic expands, the incidence of age-related conditions requiring surgical intervention will increase correspondingly.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. France is particularly strong in orthopedics, cardiovascular devices, diagnostic imaging, minimally invasive surgical technologies, and digital health. Regulatory support and funding for research and development further foster innovation. Rising surgical procedures are a key driver propelling market expansion. With more than 9 million surgical interventions performed in 2024 and surgical volumes having tripled over 45 years, the increasing volume of surgical procedures creates sustained demand for biosurgical products across all categories.Market DynamicsDriver: High and Growing Surgical Volumes Across All SpecialtiesFrance performs more than 9 million surgical interventions annually, spanning public hospitals, private clinics, and ambulatory surgical centers. Cataract surgeries lead with 1.1 million procedures, followed by hip and knee prostheses.

The breadth and depth of surgical activity in France ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. Healthcare expenditure of approximately 11.5% of GDP provides the financial infrastructure to support expanding surgical volumes. The continued expansion of surgical capacity, driven by hospital modernization and the growing network of private clinics, further reinforces this demand driver. The increase in surgical volumes is partly due to the aging of the population and technological advances that make operations safer and less painful.Challenge: Regulatory Complexity and Pricing PressureDespite the market's size and sophistication, biosurgery manufacturers face persistent challenges from regulatory complexity and pricing pressure. The European Medical Device Regulation (MDR) , which became fully applicable in May 2021, has significantly increased compliance costs and extended time-to-market for new products. The MDR requires more rigorous clinical evidence, stricter post-market surveillance, and enhanced transparency requirements, creating barriers for both established players and emerging competitors.

Additionally, France's universal healthcare system exerts significant pricing pressure through centralized reimbursement mechanisms. The Haute Autorité de Santé (HAS) evaluates the clinical value of medical devices through the CNEDiMTS for reimbursement decisions. The LPPR (Liste des Produits et Prestations Remboursables) determines which medical devices are reimbursed, and its decisions directly influence adoption rates. Manufacturers must continually demonstrate both clinical efficacy and cost-effectiveness to justify premium pricing in an increasingly cost-conscious healthcare system.Trend: Accelerating Adoption of Minimally Invasive Surgical TechniquesThe French biosurgery market is experiencing a significant trend toward minimally invasive surgical techniques. France is particularly strong in minimally invasive surgical technologies. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive applications.

Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with minimally invasive staplers are increasingly in demand. The growing awareness of minimally invasive techniques as a key driver propelling market expansion will continue to shape product development and commercial strategies. Children are also undergoing more tonsillectomies thanks to less invasive techniques.Policies• The European Medical Device Regulation (MDR) (EU) 2017/745 serves as the core regulatory framework for biosurgical products in France. Manufacturers must comply with MDR requirements for clinical evaluation, post-market surveillance, and product labeling. The French National Agency for the Safety of Medicines and Health Products (ANSM) serves as the competent authority for medical devices in France. ANSM oversees the implementation of the MDR and coordinates with notified bodies to ensure product safety and efficacy.• Ordonnance n° 2022-582, adopted on April 20, 2022, implements the MDR into French law through the Code de la santé publique (French Public Health Code).• The Haute Autorité de Santé (HAS) evaluates the clinical value of medical devices through the CNEDiMTS (National Committee for the Evaluation of Medical Devices and Health Technologies) for reimbursement decisions.• The LPPR (Liste des Produits et Prestations Remboursables) determines which medical devices are reimbursed under France's universal healthcare system, directly influencing adoption rates of biosurgical products.• Public hospital procurement accounts for the majority of device spending, with the country's 298 public hospital centers (CHU/CH) and extensive network of private clinics providing broad market access.Segment AnalysisFrance Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the French biosurgery market, driven by the high volume of orthopedic procedures.

Hip and knee prostheses are among the most frequently performed surgeries in France. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging French population with 22% aged 65 and older continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The increasing volume of surgeries and growing demand for effective hemostatic solutions contribute to the strength of this segment.• Surgical Sealants and Adhesives represent the fastest-growing product category in the French biosurgery market, driven by increasing adoption of minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses.

France is particularly strong in minimally invasive surgical technologies, creating demand for sealants compatible with these techniques.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in French hospitals and clinics.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.France Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in France, driven by the high volume of hip and knee prostheses. France is particularly strong in orthopedics. The aging French population continues to drive demand for musculoskeletal interventions, with hip and knee prostheses among the most frequently performed surgeries.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair.

Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers.• Cardiovascular Surgery represents the fastest-growing application area in the French biosurgery market, driven by the high prevalence of cardiovascular disease. France is particularly strong in cardiovascular devices. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.France Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the French biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The MDR's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the French market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life.

These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The French healthcare system's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.France Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in France, accounting for the majority of revenue. Public hospital procurement accounts for the majority of device spending, with the country's 298 public hospital centers (CHU/CH) and extensive network of private clinics providing broad market access. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the French biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by the network of private clinics, supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.France Biosurgery Market Economics• The French biosurgery market operates within a universal healthcare system characterized by public procurement, centralized reimbursement, and strong cost-containment pressures. Assurance Maladie provides broad healthcare coverage, while the LPPR determines which medical devices qualify for reimbursement.

The Haute Autorité de Santé (HAS), through CNEDiMTS, evaluates the clinical value of devices and influences reimbursement decisions. Manufacturers must demonstrate clinical efficacy, patient benefit, and economic value to obtain favorable reimbursement. Successful LPPR listing can also strengthen pricing and market-access negotiations in other European markets, making France an important strategic reference market.• Biosurgical products are procured through public hospital contracts, private clinic agreements, and surgeon preferences, with public hospitals accounting for a major share of device spending. France has 298 public hospital centers (CHU/CH) alongside an extensive network of private clinics, providing broad access to surgical markets. Its established distribution infrastructure supports nationwide product availability. France also has a strong medical-device industrial ecosystem, with more than 1,300 medical device companies operating in the country.

Skilled professionals, advanced manufacturing capabilities, and a large healthcare market make France attractive for commercial operations and investment.• France has one of Europe’s most extensive healthcare infrastructures and supports a large, highly trained surgical workforce across general surgery, orthopedics, neurosurgery, cardiovascular surgery, and other specialties. Academic medical centers and professional organizations contribute to surgical education, quality improvement, and evidence-based practice. The country is also a significant innovation center, particularly in orthopedics, cardiovascular devices, diagnostic imaging, minimally invasive surgery, digital health, and advanced biomaterials. Strong research institutions, teaching hospitals, intellectual property protection, and industry-academic collaboration provide favorable conditions for developing and commercializing innovative biosurgical technologies.• France’s medical-device regulatory framework is aligned with the European MDR and implemented through the ANSM and the Code de la santé publique, maintaining rigorous safety and quality standards. The healthcare system continues to adopt minimally invasive techniques, advanced biomaterials, and digital surgical technologies, creating opportunities for innovative biosurgical products. Long-term growth is supported by an aging population, with approximately 22% aged 65 or older, alongside high life expectancy and healthcare expenditure of around 11.5% of GDP.

As Europe’s second-largest medical device market and a leading global market, France offers substantial opportunities for manufacturers that successfully navigate reimbursement, procurement, regulation, and competition.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.